Bristol Myers Squibb, headquartered in Princeton, New Jersey, has received FDA accelerated approval for ZENBEXUS (iberdomide), the company’s first approved CELMoD therapy, for patients with multiple myeloma who have relapsed after at least one prior treatment. The drug is approved in combination with daratumumab and hyaluronidase-fihj and dexamethasone, a regimen BMS is calling ZDd, making it available to patients as early as their first relapse rather than only after multiple lines of prior therapy have failed.
What the Trial Data Actually Showed
The approval rests on Phase 3 data from the EXCALIBER-RRMM trial, which the FDA’s own approval summary confirms: 41% of patients on the ZDd regimen achieved a minimal residual disease (MRD)-negative complete response, compared with 21% of patients on the comparator regimen of daratumumab, bortezomib, and dexamethasone, a statistically significant difference (p<0.0001). MRD-negative status is a marker oncologists watch closely because it’s associated with longer progression-free survival. BMS Chief Medical Officer Dr. Cristian Massacesi framed the approval as validation of the company’s broader drug discovery approach: “Today’s approval of ZENBEXUS represents meaningful progress for patients living with multiple myeloma and underscores the power of our targeted protein degradation platform, particularly our CELMoD programs.” Dr. Sagar Lonial, the trial’s lead investigator and Chief Medical Officer of the Winship Cancer Institute at Emory University, pointed to the significance of the regimen fitting into an already familiar treatment structure: “The strong results observed with the CELMoD-based combination within a familiar triplet approach creates the potential for a new treatment foundation in multiple myeloma.” Because this is an accelerated approval, continued marketing authorization depends on BMS verifying clinical benefit in confirmatory trials.
What a CELMoD Actually Is
CELMoD stands for cereblon E3 ligase modulator, a newer class of oral targeted protein degraders that work by redirecting the body’s own protein-disposal machinery to break down proteins that cancer cells rely on to survive. ZENBEXUS is BMS’s first approved drug in this class, arriving with boxed warnings for embryo-fetal toxicity and thromboembolic events, restricted distribution through a REMS program, and a reported fatal adverse reaction rate of 4.9% in the trial population, safety tradeoffs that come with most therapies targeting an aggressive blood cancer. Heather Cooper Ortner, President and CEO of the International Myeloma Foundation, welcomed the approval from a patient-access standpoint: “Every new option gives patients and their healthcare teams additional choices as treatment needs evolve, as well as renewed hope for the future.”
Why BMS Needed This Win
The timing matters for BMS’s business, not just its pipeline. The company’s existing multiple myeloma franchise has been getting hit hard by generic competition: Revlimid sales fell 49% year-over-year to $425 million in the second quarter of 2026, and Pomalyst dropped 71% to $204 million after facing generic entrants earlier in the year, according to BioSpace’s reporting on the company’s recent results. ZENBEXUS is priced at $29,500 per 28-day cycle, and analysts have projected it could eventually generate well over $1 billion in annual sales, giving BMS a new growth driver in the same disease area where its older drugs are losing ground. It’s a pattern playing out across BMS’s portfolio broadly, replacing revenue from aging blockbusters with newer, more targeted therapies, and this approval gives the Princeton-based company a fresh entry in that race just as its legacy myeloma drugs continue to erode.
